2026 Global: Breast Biopsy Device Market-Competitive Review (2032) report
Description
The 2026 Global: Breast Biopsy Device Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Hologic, Inc.—headquartered in Marlborough, United States—dominates the breast biopsy device market through the MAMMOTOME vacuum-assisted biopsy system with accessories that enable image-guided tissue sampling. Medtronic plc, headquartered in Dublin, Ireland, maintains a substantial footprint via its portfolio of image-guided biopsy technologies and supportive surgical platforms. Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, United States, contributes through its range of biopsy needles, vacuum-assisted devices, and distribution networks that reach clinics and hospitals worldwide. Cook Medical, based in Bloomington, United States, supplies an extensive suite of biopsy systems, needles, and disposables, with broad geographical reach across North America, Europe, and Asia. Collectively, these firms underscore the market’s reliance on integrated biopsy workflows, spanning navigation guidance, needle design, and mechanical actuation. Beyond product breadth, they increasingly emphasize regulatory harmonization, data capture, and post-market surveillance to optimize diagnostic yield and patient safety. These dynamics reflect ongoing shifts toward precision sampling, patient-centered workflows, and cross-disciplinary collaboration.
Second-tier manufacturers, including Stryker Corporation, headquartered in Kalamazoo, United States, and Boston Scientific Corporation, headquartered in Marlborough, United States, hold important roles by supplying biopsy-adjacent equipment, needles, and disposables integrating with imaging guidance workflows. Stryker focuses on procedural instruments and capital equipment ecosystems that enhance retrieval and handling, while Boston Scientific provides biopsy kits, cannulas, and ultrasound-guided accessories distributed through hospital networks. Terumo Corporation, headquartered in Tokyo, Japan, contributes needle assemblies, guide-enabled devices that facilitate rapid sampling in outpatient clinics and radiology suites. The combined offerings from these companies reinforce a modular approach to breast biopsy, enabling clinicians to tailor instrument choices to lesion characteristics and patient factors. They also invest in training, procedural standardization, and post-market surveillance to minimize complications and maximize diagnostic yield across diverse care settings. As a result, cross-company collaboration and standardized protocols are increasingly common in training curricula and professional guidelines.
Mindful of the evolving regulatory and reimbursement landscapes, Philips Healthcare, headquartered in Amsterdam, Netherlands; Siemens Healthineers AG, headquartered in Erlangen, Germany; and Mindray Medical International, headquartered in Shenzhen, China, illustrate how imaging-driven biopsy workflows intersect with device performance. Philips provides diagnostic ultrasound systems and real-time imaging capabilities that enhance lesion localization and needle guidance, while Siemens Healthineers leverages its deep portfolio in radiology to offer integrated biopsy-ready platforms with advanced software. Mindray contributes affordable ultrasound solutions with portable form factors and high image quality, enabling broader adoption in community hospitals and emerging markets. Collectively, these imaging-centric players complement the core biopsy device developers by expanding access to high-quality imaging, reducing procedure times, and enabling precise tissue sampling across diverse care settings. As penetration expands in community hospitals, clinicians increasingly expect interoperable systems, standardized protocols, and robust data analytics to support continuous quality improvement. This convergence enhances procedural efficiency and patient comfort.
Hologic, Inc.—headquartered in Marlborough, United States—dominates the breast biopsy device market through the MAMMOTOME vacuum-assisted biopsy system with accessories that enable image-guided tissue sampling. Medtronic plc, headquartered in Dublin, Ireland, maintains a substantial footprint via its portfolio of image-guided biopsy technologies and supportive surgical platforms. Becton, Dickinson and Company (BD), headquartered in Franklin Lakes, United States, contributes through its range of biopsy needles, vacuum-assisted devices, and distribution networks that reach clinics and hospitals worldwide. Cook Medical, based in Bloomington, United States, supplies an extensive suite of biopsy systems, needles, and disposables, with broad geographical reach across North America, Europe, and Asia. Collectively, these firms underscore the market’s reliance on integrated biopsy workflows, spanning navigation guidance, needle design, and mechanical actuation. Beyond product breadth, they increasingly emphasize regulatory harmonization, data capture, and post-market surveillance to optimize diagnostic yield and patient safety. These dynamics reflect ongoing shifts toward precision sampling, patient-centered workflows, and cross-disciplinary collaboration.
Second-tier manufacturers, including Stryker Corporation, headquartered in Kalamazoo, United States, and Boston Scientific Corporation, headquartered in Marlborough, United States, hold important roles by supplying biopsy-adjacent equipment, needles, and disposables integrating with imaging guidance workflows. Stryker focuses on procedural instruments and capital equipment ecosystems that enhance retrieval and handling, while Boston Scientific provides biopsy kits, cannulas, and ultrasound-guided accessories distributed through hospital networks. Terumo Corporation, headquartered in Tokyo, Japan, contributes needle assemblies, guide-enabled devices that facilitate rapid sampling in outpatient clinics and radiology suites. The combined offerings from these companies reinforce a modular approach to breast biopsy, enabling clinicians to tailor instrument choices to lesion characteristics and patient factors. They also invest in training, procedural standardization, and post-market surveillance to minimize complications and maximize diagnostic yield across diverse care settings. As a result, cross-company collaboration and standardized protocols are increasingly common in training curricula and professional guidelines.
Mindful of the evolving regulatory and reimbursement landscapes, Philips Healthcare, headquartered in Amsterdam, Netherlands; Siemens Healthineers AG, headquartered in Erlangen, Germany; and Mindray Medical International, headquartered in Shenzhen, China, illustrate how imaging-driven biopsy workflows intersect with device performance. Philips provides diagnostic ultrasound systems and real-time imaging capabilities that enhance lesion localization and needle guidance, while Siemens Healthineers leverages its deep portfolio in radiology to offer integrated biopsy-ready platforms with advanced software. Mindray contributes affordable ultrasound solutions with portable form factors and high image quality, enabling broader adoption in community hospitals and emerging markets. Collectively, these imaging-centric players complement the core biopsy device developers by expanding access to high-quality imaging, reducing procedure times, and enabling precise tissue sampling across diverse care settings. As penetration expands in community hospitals, clinicians increasingly expect interoperable systems, standardized protocols, and robust data analytics to support continuous quality improvement. This convergence enhances procedural efficiency and patient comfort.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
